|
🐢
|
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
39 auth.
T. Westers,
R. Ireland,
W. Kern,
C. Alhan,
J. Balleisen,
P. Bettelheim,
K. Burbury,
M. Cullen,
J. Cutler,
M. D. Porta,
Angelika M. Drager,
J. Feuillard,
P. Font,
U. Germing,
D. Haase,
...
U. Johansson,
S. Kordasti,
M. Loken,
L. Malcovati,
J. G. Marvelde,
S. Matarraz,
T. Milne,
B. Moshaver,
G. Mufti,
K. Ogata,
A. Órfão,
A. Porwit,
K. Psarra,
S. Richards,
D. Subirá,
V. Tindell,
T. Vallespí,
P. Valent,
V. Velden,
T. Witte,
D. Wells,
F. Zettl,
M. Béné,
A. A. Loosdrecht
|
7 |
2012 |
7
🐢
|
|
🐜
|
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
21 auth.
A. Porwit,
A. A. Loosdrecht,
P. Bettelheim,
L. Brodersen,
K. Burbury,
E. Cremers,
M. D. Porta,
R. Ireland,
U. Johansson,
S. Matarraz,
...
K. Ogata,
A. Órfão,
F. Preijers,
K. Psarra,
D. Subirá,
P. Valent,
V. Velden,
D. Wells,
T. Westers,
W. Kern,
M. Béné
|
7 |
2014 |
7
🐜
|
|
🐜
|
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
35 auth.
M. D. Porta,
H. Tuechler,
L. Malcovati,
J. Schanz,
G. Sanz,
G. Garcia-Manero,
F. Solé,
John M. Bennett,
D. Bowen,
P. Fenaux,
F. Dreyfus,
H. Kantarjian,
A. Kuendgen,
A. Levis,
J. Čermák,
...
C. Fonatsch,
M. L. Beau,
M. Slovak,
O. Krieger,
Michael Luebbert,
J. Maciejewski,
S. Magalhães,
Y. Miyazaki,
M. Pfeilstöcker,
M. Sekeres,
W. Sperr,
R. Stauder,
S. Tauro,
P. Valent,
T. Vallespí,
A. A. Loosdrecht,
U. Germing,
D. Haase,
P. Greenberg,
M. Cazzola
|
6 |
2015 |
6
🐜
|
|
🐜
|
Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012
12 auth.
A. Dinmohamed,
O. Visser,
Y. Norden,
N. Blijlevens,
J. Cornelissen,
G. Huls,
...
P. Huijgens,
P. Sonneveld,
A. A. Loosdrecht,
G. Ossenkoppele,
B. Löwenberg,
M. Jongen‐Lavrencic
|
6 |
2016 |
6
🐜
|
|
🐢
|
The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system
7 auth.
C. Alhan,
T. Westers,
E. Cremers,
C. Calì,
B. Witte,
G. Ossenkoppele,
...
A. A. Loosdrecht
|
5 |
2016 |
5
🐢
|
|
🐜
|
A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies
13 auth.
G. Ossenkoppele,
B. Lowenberg,
P. Zachée,
N. Vey,
D. Breems,
A. A. Loosdrecht,
Alan H. Davidson,
G. Wells,
L. Needham,
L. Bawden,
...
M. Toal,
L. Hooftman,
P. Debnam
|
5 |
2013 |
5
🐜
|
|
🐜
|
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
8 auth.
A. Dinmohamed,
Y. Norden,
O. Visser,
E. Posthuma,
P. Huijgens,
P. Sonneveld,
...
A. A. Loosdrecht,
M. Jongen‐Lavrencic
|
5 |
2015 |
5
🐜
|
|
🐜
|
Highly variable clinical manifestations in a large family with a novel GATA2 mutation
8 auth.
Pim G. N. J. Mutsaers,
Pim G. N. J. Mutsaers,
A. A. Loosdrecht,
K. Tawana,
Csaba Bödör,
Csaba Bödör,
...
Jude Fitzgibbon,
Fred H. Menko
|
5 |
2013 |
5
🐜
|
|
🐢
|
High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes
7 auth.
C. Alhan,
T. Westers,
E. Cremers,
C. Calì,
B. Witte,
G. Ossenkoppele,
...
A. A. Loosdrecht
|
4 |
2014 |
4
🐢
|
